Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

NCT05132504 PHASE2 RECRUITING

Abbreviated Title: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Trial Phase: Phase II Clinical Indication: Pancreatic ductal adenocarcinoma; Adenocarcinoma; AJCC I, II, or III; 1st Line neoadjuvant Trial Type: Interventional prospective Type of control: Historical Route of administration: IV Treatment Groups: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Number of trial participants: 30 Estimated enrollment period: 24 months Estimated duration of trial: 3.5 Years Duration of Participation:16 months Estimated average length of treatment per patient: 16 months

Details

Lead sponsor	Baylor College of Medicine
Phase	PHASE2
Status	RECRUITING
Enrolment	30
Start date	Wed Aug 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri May 21 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Pancreatic Ductal Adenocarcinoma

Interventions

• Pembrolizumab
• Folfirinox

Countries

United States